Literature DB >> 11413121

Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis.

X Bo1, U Broome, M Remberger, S Sumitran-Holgersson.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) is considered to be a chronic autoimmune disease where infiltrating T lymphocytes have been implicated in the destruction of bile ducts. Altered function of these T cells may reflect abnormalities in the immune response leading to tissue damage. AIM: We investigated the proliferative and functional capacity of freshly isolated liver derived T lymphocytes (LDLs) and natural killer (NK) cells from PSC patients.
METHODS: The proliferative responses to common mitogens such as phytohaemagglutinin (PHA), concanavalin A (Con A), and lipopolysaccharide (LPS) were studied, and the cytotoxic function of T lymphocytes was measured using allogeneic target cells. NK (CD56(+)/16(+)) cytotoxic function was measured using the two cell lines K562 (NK sensitive) and Raji lymphoma cells (NK resistant).
RESULTS: Compared with patients with primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH), and normal controls (without liver disease), in PSC: (1) LDLs contained a low percentage of T cells; (2) there was significantly decreased expression of interleukin (IL)-2 receptor (p<0.001) on activated T cells (HLA-DR(+)); (3) LDLs but not peripheral blood lymphocytes had significantly impaired proliferative responses to mitogens such as PHA, Con A, and LPS (p< 0.001); (4) no cytotoxic activity of PSC liver T and NK cells was recorded; (5) significantly higher levels of tumour necrosis factor alpha (TNF-alpha) and IL-1beta but lower levels of IL-2, IL-10, and interferon gamma were found in the supernatants of mitogen stimulated LDL cultures (p<0.001); (6) higher percentages of freshly isolated PSC LDLs contained intracytoplasmic TNF-alpha and IL-1beta; and (7) pretreatment of PSC LDLs in vitro with neutralising TNF antibodies significantly enhanced proliferative responses and allowed IL-2 receptor expression following stimulation. In addition, the impaired cytolytic activity of both NK and T cells was partially restored. Impaired proliferative or functional capacity of liver derived T cells was not observed in either PBC or AIH patients.
CONCLUSIONS: We suggest that reduced T cell reactivity in liver infiltrating cells obtained from patients with PSC is due to high local production of TNF-alpha. Our findings indicate that the use of anti-TNF antibodies as an alternative treatment for PSC patients should be evaluated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413121      PMCID: PMC1728361          DOI: 10.1136/gut.49.1.131

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  31 in total

Review 1.  T cells in inflammatory bowel disease: protective and pathogenic roles.

Authors:  F Powrie
Journal:  Immunity       Date:  1995-08       Impact factor: 31.745

2.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

3.  Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.

Authors:  J Ludwig; S S Barham; N F LaRusso; L R Elveback; R H Wiesner; J T McCall
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

4.  Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.

Authors:  U Broomé; R Olsson; L Lööf; G Bodemar; R Hultcrantz; A Danielsson; H Prytz; H Sandberg-Gertzén; S Wallerstedt; G Lindberg
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

5.  Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis.

Authors:  W Bernal; M Moloney; J Underhill; P T Donaldson
Journal:  J Hepatol       Date:  1999-02       Impact factor: 25.083

6.  Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF.

Authors:  A P Cope; D Aderka; D Wallach; M Kahan; N R Chu; F M Brennan; M Feldmann
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

7.  Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice.

Authors:  D C Baumgart; W A Olivier; T Reya; D Peritt; J L Rombeau; S R Carding
Journal:  Cell Immunol       Date:  1998-07-10       Impact factor: 4.868

8.  Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology.

Authors:  R W Chapman; B A Arborgh; J M Rhodes; J A Summerfield; R Dick; P J Scheuer; S Sherlock
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

9.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

10.  The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells.

Authors:  A Panja; S Goldberg; L Eckmann; P Krishen; L Mayer
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

View more
  30 in total

Review 1.  Immunopathogenesis of primary sclerosing cholangitis.

Authors:  Joy Worthington; Sue Cullen; Roger Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 2.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 3.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

Review 4.  Genetics in PSC: what do the "risk genes" teach us?

Authors:  Trine Folseraas; Evaggelia Liaskou; Carl A Anderson; Tom H Karlsen
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

5.  Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.

Authors:  Zhenhua Luo; Anil G Jegga; Jorge A Bezerra
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

6.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.

Authors:  Ileana Duca; Patricia Ramírez de la Piscina; Silvia Estrada; Rosario Calderón; Katerina Spicakova; Leire Urtasun; Carlos Marra-López; Salvador Zabaleta; Raquel Bengoa; María Asunción Marcaide; Francisco García-Campos
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

7.  Periportal and sinusoidal liver dendritic cells suppressing T helper type 1-mediated hepatitis.

Authors:  Tomohiro Watanabe; Hiroaki Katsukura; Tsutomu Chiba; Toru Kita; Yoshio Wakatsuki
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

Review 8.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

Review 9.  Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Andrea T Borchers; Shinji Shimoda; Christopher Bowlus; Carl L Keen; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

Review 10.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.